利巴韦林与单磷酸阿糖腺苷治疗手足口病的疗效观察

Observation on the curative effect of ribavirin and vidarabine monophosphate in the treatment on hand foot and mouth disease

目的:观察单磷酸阿糖腺苷治疗手足口病的疗效和安全性。方法:2013年1-12月收治手足口病患儿351例,按就诊顺序将其随机分为治疗组和对照组,治疗组176例给予单磷酸阿糖腺苷静滴,1次/d,对照组175例给予利巴韦林注射液静滴,1次/d,疗程均为5 d。观察两组临床症状及体征的变化及不良反应。结果:治疗组和对照组的总有效率分别为98.9%和88%,两组比较差异有统计学意义(P<0.05),治疗组未发现明显不良反应。结论:与利巴韦林相比,单磷酸阿糖腺苷治疗手足口病疗效显著,安全可靠,值得临床推广。

Objective:To observe the efficacy and safety of vidarabine monophosphate in the treatment of hand foot mouth disease.Methods:351 patients with hand foot and mouth disease were selected from January to December 2013.They were randomly divided into the treatment group and the control group according to the order of treatment.176 cases in the treatment group were given vidarabine intravenous infusion,1 time/d.175 cases in the control group were given ribavirin injection intravenous infusion,1time/d.The course of treatment both were 5 d.Then we observed the changes of the clinical symptoms,signs and adverse reaction between two groups.Results:The total effective rate of the treatment group and the control group were 98.9% and 88% respectively,and the difference was statistically significant between two groups(P<0.05).There was no obviously adverse reaction in the treatment group.Conclusion:Compare with ribavirin,the efficacy of vidarabine monophosphate is better in the treatment of hand foot mouth disease,and more safe and reliable,so it is worthy of clinical application.